Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

In drug-naïve subjects with type 2 diabetes ... The studies presented thus far therefore suggest that DPP-4 inhibition is an efficient treatment of type 2 diabetes, both as monotherapy and ...

The rise in type 2 diabetes has become a significant public health concern in recent years. This form of diabetes happens ...

Certain medications, such as steroids ... along with any side effects they may have. DPP-4 inhibitors help lower blood sugar levels only when they’re elevated. They do this by blocking the ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

There is also a strong rationale provided to avoid use of sliding-scale insulin and to consider the use of oral agents and ...

The DPP-4 drugs and GLP-1 agonist drugs such as AstraZeneca’s Byetta have also been suspected of increasing the risk of pancreatitis, but an EMA-led review concluded in August there was no firm ...

A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

Good news for people with diabetes who can enjoy better kidney health as well as ward off gout, thanks to a pioneering ...

Nearly 7 million Americans 65 and older are living with Alzheimer's disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks. LIGHTFIELD STUDIOS - stock ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...